Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan recently teamed up with Nature Medicine to host a symposium on the latest ground-breaking research into cancer diagnosis and treatment, from novel biomarkers to personalized vaccines and cell-based therapies. A select group of industry leaders...
Tecan Gives Back is an employee-driven initiative supporting charities that help to improve people’s health and quality of life. Created as part of the company’s 40th anniversary celebrations, the scheme gives employees the opportunity to earn...
Multiple myeloma (MM) remains an incurable blood cancer, but recent advancements in treatment have significantly improved patient prognosis and quality of life. UK-based specialist diagnostic company The Binding Site has developed a new strategy...
Prostate cancer is the second most common cancer in men, killing hundreds of thousands each year. However, the current routine screening method for checking prostate-specific antigen (PSA) levels generates false positives in an alarming number of...
In his book The Emperor of All Maladies, Siddhartha Mukherjee tells the story of one of the turning points in the history of cancer medicine. A turning point that he dates to May 1947.
Massively parallel sequencing has rapidly become a must-have tool of the trade in molecular biology and drug discovery research. In recent years, the cost of next generation sequencing (NGS) has declined exponentially, while throughput, accuracy and...